| Code | CSB-RA004888MA5HU |
| Size | US$210 |
| Order now | |
| Image | |
| Have Questions? | Leave a Message or Start an on-line Chat |
| Application | Recommended Dilution |
|---|---|
| FC | 1:50-1:200 |
CD19 serves as a critical B-cell lineage marker, functioning as a co-receptor that modulates B-cell receptor signaling thresholds and plays essential roles in B-cell development, activation, and differentiation. Its consistent expression throughout B-cell maturation—from early pro-B cells through mature B lymphocytes—has established CD19 as an indispensable target in immunology research, B-cell malignancy studies, and the rapidly expanding field of CAR-T cell therapy development.
This recombinant monoclonal antibody, derived from clone 12E8, offers the reproducibility and consistency that demanding research applications require. Unlike traditional hybridoma-derived antibodies, recombinant production ensures sequence-defined specificity with minimal lot-to-lot variation, allowing you to maintain experimental continuity across long-term studies. The scFv-his format provides a compact binding module with an integrated His-tag, facilitating straightforward detection using anti-His secondary reagents.
Validated for flow cytometry and ELISA applications, this antibody demonstrates reliable performance for B-cell identification and quantification workflows. Flow cytometry validation using Raji cells—a well-characterized Burkitt lymphoma B-cell line—confirms specific detection of human CD19 at working concentrations of 2 µg per million cells, with recommended dilutions ranging from 1:50 to 1:200 for optimal signal-to-background ratios. The unconjugated format provides flexibility for pairing with your preferred secondary detection system.
Supplied in a glycerol-stabilized PBS buffer with Proclin 300 preservative, this antibody maintains stability during storage at -20°C or -80°C. Whether you are characterizing B-cell populations, investigating B-cell signaling pathways, or developing immunotherapeutic approaches targeting CD19-positive malignancies, this recombinant antibody delivers the specificity and batch consistency your research demands.
There are currently no reviews for this product.